The E.O.R.T.C. Phase II Studies in Advanced Prostatic Cancer
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)
The E.O.R.T.C. Urological Group has had many difficulties in the evaluation of the treatment results of their phase II and III trials in prostatic cancer.
KeywordsResponse Criterion Partial Remission Measurable Lesion Soft Tissue Lesion Supraclavicular Lymph Node
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- 4.W.D. DeWijs, M. Bauer, J. Colsky, R.A. Cooper, R. Creech, and P.P. Carbone, Comparative Trial of Adriamycin and 5-Fluorouracil in Advanced Prostatic Cancer — Progress Report, Cancer Treatment Rep. 61:325 (1977).Google Scholar
- 5.W.D. DeWijs and C.B. Begg, Comparison of Adriamycin and 5-Fluorouracil in Advanced Prostatic Cancer, Abstract Amer. Soc. Clin. Oncol. 19:331 (1978).Google Scholar
- 6.L.K. Kvols, R.T. Eagan, and R.P. Myers, Evaluation of Melphalan, ICRF-159, and Hydroxyurea in Metastatic Prostate Cancer: a Preliminary Report, Cancer Treatment Rep. 61:311 (1977).Google Scholar
- 7.R. Sylvester, E.O.R.T.C. Data Center, Personal Communication, (1981).Google Scholar
- 8.Definitions of Objective Response, in: “W.H.O. Handbook for Reporting Results of Cancer Treatment,” W.H.O. Offset Publication, Geneva, 48:23 (1979).Google Scholar
© Springer Science+Business Media New York 1983